Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Activin A antibody
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
An anti-Activin A antibody is a therapeutic monoclonal antibody designed to bind and neutralize Activin A, a member of the transforming growth factor-beta (TGF-beta) superfamily. Activin A plays a critical role in various physiological and pathological processes, including bone remodeling, inflammation, and muscle wasting. In the context of the rare genetic disorder fibrodysplasia ossificans progressiva (FOP), mutations in the ACVR1 receptor cause it to abnormally perceive Activin A as an activating ligand, driving progressive heterotopic ossification (HO). By neutralizing Activin A, anti-Activin A antibodies block this aberrant signaling pathway, preventing ectopic bone formation and reducing painful tissue flare-ups. The leading clinical candidate in this class is Regeneron's garetosmab (Pasatru), which received FDA approval in August 2026 for the treatment of adults with FOP. Additionally, anti-Activin A antibodies are being explored in combination therapies for muscle preservation and fat loss in obesity management.
- Other names
- Activin A antibodyanti-Activin A monoclonal antibodyanti-Activin-A antibody
02
Targets
Activin A
Beyond the preview
Go deeper on anti-Activin A antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Activin A antibody.